Aptiom

— THERAPEUTIC CATEGORIES —
  • Seizure disorders

Aptiom Generic Name & Formulations

General Description

Eslicarbazepine acetate 200mg+, 400mg, 600mg+, 800mg+; (+) scored tabs.

Pharmacological Class

Dibenzazepine.

How Supplied

Tabs 200mg, 400mg—30; 600mg—60, 90; 800mg—30, 90

Manufacturer

Generic Availability

NO

Aptiom Indications

Indications

Monotherapy or adjunctive treatment of partial-onset seizures.

Aptiom Dosage and Administration

Adult

Initially 400mg once daily; for some patients, may initiate at 800mg once daily if need for seizure reduction outweighs an increased risk of adverse reactions. Increase dose in weekly increments of 400–600mg, based on response and tolerability, to maintenance dose of 800–1600mg once daily. Patients on monotherapy: consider 800mg once daily if 1200mg/day not tolerated. Patients on adjunctive therapy: consider 1600mg/day if 1200mg/day is inadequate. Moderate and severe renal impairment (CrCl <50mL/min): reduce doses by 50%.

Children

<4yrs: not established. Give once daily. Dose increase should be based on response and tolerability, no more than once per week. 4–17yrs (11–21kg): initial and max titration increment: 200mg/day; maintenance: up to 400–600mg/day; (22–31kg): initial and max titration increment: 300mg/day; maintenance: up to 500–800mg/day; (32–38kg): initial and max titration increment: 300mg/day; maintenance: up to 600–900mg/day; (>38kg): initial and max titration increment: 400mg/day; maintenance: up to 800–1200mg/day. Moderate and severe renal impairment (CrCl <50mL/min): reduce doses by 50%.

Aptiom Contraindications

Contraindications

Hypersensitivity to oxcarbazepine.

Aptiom Boxed Warnings

Not Applicable

Aptiom Warnings/Precautions

Warnings/Precautions

Increased risk of suicidal thinking or behavior; monitor for clinical worsening or unusual changes. Discontinue if serious dermatologic reactions or DRESS/multiorgan hypersensitivity, anaphylaxis, angioedema occurs. Measure serum sodium and chloride levels during therapy and esp. if hyponatremia symptoms develop. Monitor for neurological adverse reactions (esp. in elderly). Monitor LFTs at baseline; discontinue if jaundice or evidence of significant liver injury occurs. Severe hepatic impairment: not recommended. Avoid abrupt cessation. Pregnancy. Nursing mothers.

Aptiom Pharmacokinetics

See Literature

Aptiom Interactions

Interactions

Avoid adjunctive therapy with oxcarbazepine. Antagonized by carbamazepine, phenobarbital, phenytoin, and primidone; monitor and adjust dose. May potentiate phenytoin, clobazam, omeprazole. May antagonize simvastatin, lovastatin. May decrease effectiveness of oral contraceptives; use additional non-hormonal forms. May affect thyroid function tests. Caution with other drugs known to decrease serum sodium. Monitor INR when given with warfarin.

Aptiom Adverse Reactions

Adverse Reactions

Dizziness, somnolence, nausea, headache, diplopia, vomiting, fatigue, vertigo, ataxia, blurred vision, tremor; hyponatremia, liver injury; rare: serious skin reactions (eg, SJS, TEN), DRESS/multiorgan hypersensitivity, anaphylaxis, angioedema, blood dyscrasias (discontinue if occur).

Aptiom Clinical Trials

See Literature

Aptiom Note

Notes

To enroll in the North American Antiepileptic Drug Pregnancy Registry call (888) 233-2334.

Aptiom Patient Counseling

See Literature

Images